Molecular diagnostic firm Amoy Diagnostics has gained Chinese regulatory approval for its liquid biopsy test for lung cancer, the first of its kind to be cleared by the China Food and Drug Administration. The company said it had received clearance from China's National Health Commission on May 20 after a trial in which patients were given an oral fluid sample containing their cancer cells before being sent home with instructions not
Molecular diagnostic firm Amoy Diagnostics has gained Chinese regulatory approval for its liquid biopsy test for lung cancer, the first of its kind to be cleared by the China Food and Drug Administration. The company has developed a technique able to detect EGFR gene mutations in plasma samples by identifying circulating tumour DNA through a non-invasive procedure.